Encapsulation of 9-nitrocamptothecin, a novel anticancer drug, in biodegradable nanoparticles: Factorial design, characterization and release kinetics

被引:147
作者
Derakhshandeh, K.
Erfan, M.
Dadashzadeh, S.
机构
[1] Shahid Beheshti Univ Med Sci, Sch Pharm, Dept Pharmaceut, Tehran, Iran
[2] Shahid Beheshti Univ Med Sci, Pharmaceut Sci Res Ctr, Tehran, Iran
关键词
9-nitrocamptothecin; PLGA; nanoparticles; full factorial experimental design; release kinetics;
D O I
10.1016/j.ejpb.2006.09.004
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study was aimed at developing a polymeric drug delivery system for a new and potent antitumor drug, 9-nitrocamptothecin (9-NC), intended for both intravenous administration and improving the therapeutic index of the drug. To achieve these goals, 9-NC loaded poly(DL-lactide-co-glycolide) (PLGA) nanoparticles were prepared by nanoprecipitation method and characterized. The full factorial experimental design was used to study the influence of four different independent variables on response of nanoparticle drug loading. Analysis of variance (ANOVA) was used to evaluate optimized conditions for the preparation of nanoparticles. The physical characteristics of PLGA nanospheres were evaluated using particle size analyzer, scanning electron microscopy, differential scanning calorimetry and X-ray diffractometry. The results of optimized formulations showed a narrow size distribution with a polydispersity index of 0.01%, an average diameter of 207 +/- 26 nm, and a drug loading of more than 30%. The in vitro drug release profile showed a sustained 9-NC release up to 160 h indicating the suitability of PLGA nanoparticles in controlled 9-NC release. Thus prepared nanoparticles described here may be of clinical importance in both stabilizing and delivering camptothecins for cancer treatment. (c) 2006 Elsevier B.V. All rights reserved.
引用
收藏
页码:34 / 41
页数:8
相关论文
共 38 条
[1]  
Baker R. W., 1974, Controlled Release of Biologically Active Agents, P15
[2]   Encapsulation of hydrophilic and lipophilic drugs in PLGA nanoparticles by the nanoprecipitation method [J].
Barichello, JM ;
Morishita, M ;
Takayama, K ;
Nagai, T .
DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 1999, 25 (04) :471-476
[3]   RECENT ADVANCES ON THE USE OF BIODEGRADABLE MICROPARTICLES AND NANOPARTICLES IN CONTROLLED DRUG-DELIVERY [J].
BRANNONPEPPAS, L .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1995, 116 (01) :1-9
[4]   Nanoparticles in cancer therapy and diagnosis [J].
Brigger, I ;
Dubernet, C ;
Couvreur, P .
ADVANCED DRUG DELIVERY REVIEWS, 2002, 54 (05) :631-651
[5]   Liquid chromatographic quantitation of the lactone and the total of lactone and carboxylate forms of 9-nitrocamptothecin in human plasma [J].
Derakhshandeh, K ;
Dadashzadeh, S .
JOURNAL OF CHROMATOGRAPHY B-ANALYTICAL TECHNOLOGIES IN THE BIOMEDICAL AND LIFE SCIENCES, 2005, 818 (02) :199-204
[6]  
Drummond DC, 1999, PHARMACOL REV, V51, P691
[7]   A KINETIC AND MECHANISTIC STUDY OF THE HYDROLYSIS OF CAMPTOTHECIN AND SOME ANALOGS [J].
FASSBERG, J ;
STELLA, VJ .
JOURNAL OF PHARMACEUTICAL SCIENCES, 1992, 81 (07) :676-684
[8]   NANOCAPSULE FORMATION BY INTERFACIAL POLYMER DEPOSITION FOLLOWING SOLVENT DISPLACEMENT [J].
FESSI, H ;
PUISIEUX, F ;
DEVISSAGUET, JP ;
AMMOURY, N ;
BENITA, S .
INTERNATIONAL JOURNAL OF PHARMACEUTICS, 1989, 55 (01) :R1-R4
[9]  
Garcia-Carbonero R, 2002, CLIN CANCER RES, V8, P641
[10]   Topoisomerase I inhibitors: the relevance of prolonged exposure for present clinical development [J].
Gerrits, CJH ;
deJonge, MJA ;
Schellens, JHM ;
Stoter, G ;
Verweij, J .
BRITISH JOURNAL OF CANCER, 1997, 76 (07) :952-962